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Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus:
Insights From the DCCT/EDIC Study
W.H. Wilson Tang, MD; Paula McGee, MS; John M. Lachin, ScD; Daniel Y. Li, BS; Byron Hoogwerf, MD; Stanley L. Hazen, MD, PhD;
DCCT/EDIC Research Group*
Background-—Hyperglycemia leading to increased oxidative stress is implicated in the increased risk for the development of
macrovascular and microvascular complications in patients with type 1 diabetes mellitus.
Methods and Results-—A random subcohort of 349 participants was selected from the DCCT/EDIC (Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and Complications) cohort. This included 320 controls and 29
cardiovascular disease cases that were augmented with 98 additional known cases to yield a case cohort of 447 participants (320
controls, 127 cases). Biosamples from DCCT baseline, year 1, and closeout of DCCT, and 1 to 2 years post-DCCT (EDIC years 1
and 2) were measured for markers of oxidative stress, including plasma myeloperoxidase, paraoxonase activity, urinary F2a
isoprostanes, and its metabolite, 2,3 dinor-8 iso prostaglandin F2a. Following adjustment for glycated hemoblobin and weighting
the observations inversely proportional to the sampling selection probabilities, higher paraoxonase activity, reflective of antioxidant
activity, and 2,3 dinor-8 iso prostaglandin F2a, an oxidative marker, were significantly associated with lower risk of cardiovascular
disease (4.5% risk for 10% higher paraoxonase, P<0.003; 5.3% risk for 10% higher 2,3 dinor-8 iso prostaglandin F2a, P=0.0092).
In contrast, the oxidative markers myeloperoxidase and F2a isoprostanes were not significantly associated with cardiovascular
disease after adjustment for glycated hemoblobin. There were no significant differences between DCCT intensive and conventional
treatment groups in the change in all biomarkers across time segments.
Conclusions-—Heightened antioxidant activity (rather than diminished oxidative stress markers) is associated with lower
cardiovascular disease risk in type 1 diabetes mellitus, but these biomarkers did not change over time with intensification of
glycemic control.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identifiers: NCT00360815 and NCT00360893. ( J Am
Heart Assoc. 2018;7:e008368. DOI: 10.1161/JAHA.117.008368.)
Key Words: diabetes mellitus • F2Isoprostane • free radical • paraoxonase
T he DCCT (Diabetes Control and Complications Trial) andits observational follow-up study, the EDIC (Epidemiology of Diabetes Interventions and Complications),showed that intensive therapy to lower glycated hemoglobin
(HbA1c) to near-normal concentrations reduces the risk of
any cardiovascular disease (CVD) event in patients with type 1
diabetes mellitus (T1DM).1–3 Despite the landmark study’s
conclusion that intensive therapy has long-term beneficial
effects on the risk of CVD,4 the precise mechanisms by which
cardiovascular complications of diabetes mellitus occur are
still not well understood. Early studies have focused on the
changes in lipoprotein levels as biomarkers for diabetes
mellitus complications; specifically, oxidative modification of
low-density lipoprotein is believed to play a causative role in
the development of atherosclerotic disease as well as
microvascular complications of T1DM.5–9 Although lipoprotein
markers have proved to be important for assessing cardio-
vascular risk, they do not completely account for the excess
cardiovascular risk in diabetes mellitus.
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Hyperglycemia leading to increased oxidative stress has
been implicated as a key pathophysiological factor of
macrovascular complications in T1DM.10 Through the use of
specific measures of oxidative stress in the setting of
known CVD-reducing therapies such as 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase inhibitors, strong correlations
between distinct oxidative pathways and atherosclerotic
disease have been established in the general population.11
Leukocyte-derived oxidant production is triggered by gran-
ulocyte peroxidases such as myeloperoxidase (MPO).12
Furthermore, reactive species produced by activated neu-
trophils and other sources can lead to lipid peroxidation of
the cellular membrane and the production of prostaglandin-
like compounds such as F2-isoprostane (F2IP) and its major
metabolite, 2,3 dinor-8 iso prostaglandin F2a (2,3-dinor-
iPF2a-III).
13–15 Conversely, important high-density lipoprotein
components such as paraoxonases (PON) are antioxidants
that can prevent the accumulation of lipid peroxides.16
Finally, the widely distributed antioxidant enzyme, PON1,
is closely associated with HDL.17 Low levels of PON1 have
consistently been associated with susceptibility to coronary
heart disease in various case-control studies.18,19 Addition-
ally, mouse models of PON1 overexpression have sug-
gested the ability of PON to inhibit development of
atherosclerosis in metabolic syndrome.20,21 Because these
associations have not been fully explored in T1DM, we
assess the link between oxidative pathways and the risk for
CVD as well as its relationship to chronic glycemic control
in a longitudinal case-cohort substudy of the DCCT/EDIC
patient population.
Methods
The data, analytical methods, and study materials will be/have
been made available to other researchers through the National
Institute of Diabetes and Digestive and Kidney Disease Data
Repository for purposes of reproducing the results or replicat-
ing the procedure.22 These include the multiply imputed data
sets that were constructed to account for missing data and the
computer programs used to generate the tables herein.
Study Population
The DCCT was a randomized controlled trial of 1441 patients
who were between the ages of 13 and 39 years. Approximately
half the subjects were enrolled in a primary prevention cohort
with no pre-existing microvascular complications and 1 to
5 years’ duration of T1DM, and half to a secondary intervention
cohort with mild pre-existing retinopathy, possible microalbu-
minuria, and 1 to 15 years’ duration preceding study entry.23
At baseline, patients with a history of CVD, hypertension (blood
pressure of 140/90 mm Hg or more), or hypercholesterolemia
(fasting serum cholesterol 3 SDs above age- and sex-specific
means) were excluded. Participants were assigned to either
intensive therapy aimed at achieving chronic glycemic levels as
close to the nondiabetic range as safely possible, or to
conventional therapy that aimed to avoid symptomatic hyper-
glycemia and hypoglycemia. The cohort was followed for an
average of 6.5 years. Following DCCT, 97% of the surviving
original cohort agreed to join the observational follow-up study,
the EDIC. The DCCT and EDIC studies were approved by the
institutional review boards of all participating institutions, and
each participant provided written informed consent.
Case-Cohort Design
A case-cohort design was used to assess the association of
oxidative biomarkers of interest with CVD cases who had
experienced an incident CVD event during the DCCT or during
the first 16 years of follow-up in EDIC.1 CVD events were
defined as fatal or nonfatal myocardial infarction or stroke and
death judged to be attributed to CVD, subclinical myocardial
infarction present on an annual ECG, angina confirmed by
ischemic changes on exercise tolerance testing, or by
clinically significant obstruction on coronary angiography or
coronary bypass.
A sample of 125 cases with a sample of 250 control
subjects would provide 85% power to detect a hazard ratio
(approximately equal to an odds ratio) of 1.39 per SD
difference using a score test in the stratified Cox regression
model at the 0.05 level 2-sided.24
At the time that the sample was selected, a total of 127
subjects had experienced at least 1 CVD event (cases). A
Clinical Perspective
What Is New?
• We observed that heightened antioxidant activity (as
measured by paraoxonase-1 activity), rather than dimin-
ished markers of oxidative stress, is associated with lower
cardiovascular disease risk in patients with type 1 diabetes
mellitus.
• We also observed that none of the biomarkers improved
over time with intensification of glycemic control.
What Are the Clinical Implications?
• Hyperglycemia has been associated with increased oxida-
tive stress, which has long been implicated in the increased
risk for the development of macrovascular and microvascu-
lar complications in patients with type 1 diabetes mellitus.
• These findings challenged past reports and suggest that
intrinsic counter-regulatory mechanisms such as paraox-
onase-1 activity may play an important role in cardiopro-
tection in patients with type 1 diabetes mellitus.
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subcohort of 350 subjects was randomly selected from the
DCCT cohort of 1441 subjects. No specimens were available
for 1 patient, who was deleted. This subcohort included 29
CVD cases, leaving 320 controls without past CVD. To this,
we added the remaining 98 then-known CVD cases, yielding a
study sample of 447 subjects (127 CVD cases+320 controls).
Biospecimens
Patient blood and urine samples were collected as part of the
DCCT/EDIC study. Oxidative stress markers were measured
on stored biosamples from 4 time points: DCCT baseline,
DCCT year 1, DCCT closeout (mean 6.5 years of treatment),
and EDIC years 1 to 2.
Laboratory Analysis
HbA1c was measured quarterly during the DCCT and annually
during EDIC using a high-precision, high-performance liquid
chromatography assay with long-term control subjects to
monitor assay stability as described.25 During DCCT, fasting
lipid and serum creatinine levels and other risk factors for
CVD were measured annually. During EDIC, fasting lipid levels
and renal function were measured in alternate years.
Serum paraoxonase activity was determined using spec-
trophotometry in a 96-well plate format (Spectramax 384 Plus;
Molecular Devices, Sunnyvale, CA) as previously described.24
Rate of generation of paranitrophenol was determined at
405 nm in 40-fold diluted serum (final) in reaction mixtures
composed of 1.5 mmol/L of paraoxon (Sigma-Aldrich, St.
Louis, MO), 10 mmol/L of Tris hydrocholoride, pH 8, 1 mol/L
of sodium chloride, and 2 mmol/L of calcium chloride at 24°C.
An extinction coefficient (at 405 nm) of 17 000 mol/L/cm
was used for calculating units of paraoxonase activity, which is
expressed as nmol/L of paranitrophenol produced per minute
per milliliter of serum. The intra-assay and interassay coeffi-
cients of variance (CVs) for the high-throughput PON1 activity
assay were 1.9% and 3.3%, respectively, on 30 replicates
performed on 15 different days. Plasma concentrations of
MPO were determined by MPO assay on a Siemens Dimension
XPand analyzer for EDTA plasma, with intra-assay CV of 2.2%
and interassay CV of 3.5%. Quantitation of urine metabolites
F2-IP and 2,3-dinor-iPF2a-III were measured by stable isotope
dilution liquid chromatography/tandem mass spectrometry
analysis as previously described.26 The interday assay CV
reported for the 2 assays averaged 10%, whereas the interday
assay CV averaged 10.6%.26
Statistical Analysis
Owing to depletion of saved specimens from past DCCT/EDIC
ancillary studies, 261 of the 1759 (15%) expected samples
were missing, 255 owing to depletion and only 6 owing to loss
to follow-up. To address these missing data, multiple impu-
tation was used to provide 10 estimates of each missing value
and yielding 10 complete data sets.27 A given analysis was
then repeated using each of the 10 complete data sets, and
the results were averaged using the methods of Rubin and
Schenker.28 The resulting confidence limits and P values
accounted for the overall extent of the missing original data.
A survey sampling analysis using weights inversely
proportional to the sampling probability was used to describe
the characteristics of the weighted subsample in comparison
to the full cohort.29 Mean values of the biomarkers over time
with tests of treatment group differences were obtained using
survey sampling regression models.29
Separate analyses of the association of each natural log-
transformed biomarker with the risk of an initial CVD event
were conducted using Barlow’s modified Cox proportional
hazards model for application to a case-cohort design that used
the survey weights equal to the inverse of the subcohort
sampling probabilities.30,31 Cox proportional hazards models
within each group were stratified by baseline cohort and the
models in the combined groups were also stratified by
treatment group. All associations are presented as the percent
change in CVD risk per 10% increase in the biomarker, with and
without adjustment for HbA1c as a time-dependent covariate.
The biomarker entered the model as a time-dependent
covariate with the biomarker value at each of the 4 measure-
ment times. The time-dependent HbA1c covariate value used
the eligibility screening value at baseline, the mean over the
first year at year 1, the mean up to closeout at closeout, and the
mean over DCCT and EDIC up to EDIC year 1 or 2. Additional
models tested group by biomarker interaction effects.
The Appendix S1 provides a technical description of the
statistical methods and the software that were used.
Results
The weighted estimates of patient characteristics in the total
case-cohort sample (N=447) were similar to the aggregate
estimates in the original complete DCCT cohort (N=1441),
and the validity of the inverse probability weighted analyses
was verified (Table 1).
Table 2 describes the mean values of the biomarkers over
the selected study period, with tests of significant differences
within and across treatment groups and points in time. A
significant difference (P<0.05) between baseline and DCCT
year 1 was observed within both the intensive and conven-
tional treatment groups (separately) for 2,3-dinor-iPF2a-III and
for F2IP, but with no significant difference between groups.
Changes between DCCT closeout and EDIC year 1 to 2 were
not significant within either treatment group and did not differ
between groups.
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Table 3 presents the association of each biomarker (natural
log-transformed) as a time-dependent covariate with the risk of
CVD separately within the intensive and conventional groups,
and the 2 combined, without and with adjustment for time-
dependent HbA1c. After adjustment for time-dependent
HbA1c, for a 10% increase in PON, the risk of CVD lowers by
4.5% (P=0.0026) in the total cohort, and by 4.6% (P=0.0125) in
the conventional group. Similar effects were observed without
the HbA1c adjustment, as well as a nominally significant
reduction by 4.8% in the intensive group (P=0.046).
For a 10% increase in 2,3-dinor-iPF2a-III, the risk of CVD
lowers by 5.3% (P=0.0092) in the total cohort, and by 6.4%
(P=0.026) in the intensive group, with similar associations
without the HbA1c adjustment. There was a marginally
significant 8.1% reduction in CVD risk with a 10% increase
in F2IP (P=0.034) without adjustment for HbA1c that became
nonsignificant after such adjustment (P=0.057). In contrast,
MPO was not significantly associated with CVD in either group
or total, without or with adjustment for HbA1c.
In general, the effect sizes within each group are similar, if
not greater, than in total; however, the P values within each
group could be nonsignificant owing to the smaller sample
size within each group. A test of interaction did not show any
significant differences in the biomarker effects between
groups.
Discussion
Strong evidence has tied oxidative stress to the development of
CVD in the general population. In this study, we utilize
biomarkers that are distinct elements of the oxidative process.
There are several novel findings in this study. First, we observed
that none of our oxidative stress biomarkers changed over time
in either treatment group and did not differ significantly
between groups during the course of the study. Second,
increases in all but MPOwere associated with lower risk of CVD
with and without adjustment for HbA1c as a time dependent
covariate (marginally for F2IP after adjustment). These results
suggest that despite their associations with lower CVD risk,
biomarkers of oxidative stress are largely unaffected by
intensification of glycemic control in this prospectively ran-
domized study of patients with T1DM. These findings are
surprising given previous DCCT/EDIC studies showing
increased oxidized low-density lipoprotein and advanced gly-
cation end products as predictors of increased coronary artery
calcification or carotid artery intimamedial thickness.5,7,8 The
discrepancy may suggest different mechanisms by which
modified low-density lipoprotein forms contribute to disease
beyond those reflected by our panel of markers. Furthermore,
carotid artery intimamedial thickness and coronary artery
calcification are surrogate measures of atherosclerosis and do
not directly indicate clinical events. For example, carotid
intimamedial thickness is not recommended for routine
measurement in clinical practice for risk assessment for a first
atherosclerotic CVD event by recent American College of
Cardiology/American Heart Association guidelines,32 whereas
coronary artery calcification scores are generally weighted
upward for greater calcium density. However, more-recent data
have suggested that increased plaque calcium density may be
inversely correlated with CVD risk.33
Similar to the oxidative marker findings, we observed an
association between higher antioxidant PON activity and
lower CVD risk in this cohort, especially in the conventional
treatment group, both unadjusted and adjusted for HbA1c. An
additional analysis (not shown) adjusted for high-density
lipoprotein levels and smoking status at the time of each
biomarker measurement provided concordant results.
Diminished PON activity has been linked with T1DM in
several studies.34–38 Paraoxonases constitute a family of
calcium-dependent esterases with 3 isoforms: PON1, PON2,
and PON3, with PON1 being the primary form found in
serum.39 Whereas all 3 isoforms exhibit arylesterase and
paraoxonase activities, the native enzymatic activity of PON is
thought to be as a lactonase that may modify several
prodrugs.39 Studies have shown that both the more-abundant
PON1, as well as PON3, bind to the high-density lipoprotein
particle and circulate.40 These pleiotropic enzymes are
genetically highly conserved across species, and their diverse
roles include protection against lipid peroxidation and oxida-
tive stress, modulation against endoplasmic reticulum stress,
and regulation of cell proliferation and apoptosis.41 Dimin-
ished serum PON paraoxonase and arylesterase activities
Table 1. Baseline Characteristics of the DCCT/EDIC Case-
Control and Total Cohorts
Weighted Case-Control
Cohort
Total
DCCT Cohort
N 447 1441
Age, y 26.77.3 26.87.1
Female, % 46 47
Primary prevention cohort, %* 51 50
Intensive treatment group, % 49 49
Diabetes mellitus duration, mo 69.250.9 67.649.9
Body mass index, kg/m2 23.52.7 23.52.8
HbA1c, % 8.81.5 8.91.6
HbA1c, mmol/mol 73.216.4 74.017.5
Unless otherwise indicated, data are meansSD or % estimated using the survey sample
weights based on the inverse sampling probabilities within strata defined by primary vs
secondary cohort, intensive vs conventional treatment, and CVD case vs control. CVD
indicates cardiovascular disease; DCCT, Diabetes Control and Complications Trial; EDIC,
Epidemiology of Diabetes Interventions and Complications; HbA1c, glycated hemoglobin.
*Primary prevention cohort and secondary intervention cohort are based on the original
DCCT study design, see Methods.
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have been directly associated with increased circulating levels
of structurally defined specific oxidized fatty acids42 and may
provide incremental prognostic value in stable cardiac
patients, even among those with no significant coronary
artery stenosis by angiography who might otherwise be
dismissed as low risk.24 Meanwhile, serum PON activity levels
strongly tracked with genetic polymorphisms linked to PON1
genotype (especially Q192R), thus confirming the contribution
of PON1 in these esterase activities. It has been reported that
glycation and glycoxidation of PON1 substantially reduces the
ability for PON1 to metabolize membrane lipid hydroperoxides
in vitro.43 Therefore, it is interesting that PON1 did not appear
to attenuate long-term CVD risk despite the intensification of
glycemic control in T1DM given the similar mechanisms of
hemoglobin and PON glycation.
Enhanced oxidative stress as a result of free radical lipid
peroxidation can be measured by increased levels of F2IP,
which has long been considered 1 of the gold standards for
the assessment of in vivo oxidative stress.15,44 Also, F2IP and
its metabolites, such as 2,3-dinor-iPF2a-III, have been consis-
tently found to be higher in smokers.45 However, despite that
the majority of studies that have been performed on F2IP as a
risk marker have been cross-sectional,46 a relationship
between F2IP and atherosclerotic risk has been established.
47
In contrast, lower 2, 3-dinor-iPF2a-III (and to some extent F2IP)
was associated with higher CVD risk in DCCT/EDIC. These
unexpected observations were inconsistent with the associ-
ation between these indices of oxidative stress and glycemic
control in children and adolescents with T1DM.48–50
Furthermore, our findings did not support the notion that
intensification of glycemic control confers any improvement in
F2IP and 2,3-dinor-iPF2a-III levels over time. Whereas in T1DM,
insulin action may contribute to enhancement in antioxidant
effects and help explain the stability of the observed oxidative
markers over time, we do not find it likely that this actually
plays a large role in our study. In a previous assessment of
risk factors for CVD and major atherosclerotic cardiovascular
events, daily insulin dose did not emerge in the final model for
CVD or major atherosclerotic cardiovascular events. Insulin
dose alone did have a nominally significant association with
risk of any CVD, but was not significant in a model with other
factors.51
In contrast to the F2IP formed as a product of numerous
oxidative mechanisms, MPO serves as a catalytic source of
specific oxidative processes often associated with inflamma-
tion, including generation of reactive nitrogen and chlorinating
species. Multiple studies have found MPO to be a prognostic
marker for CVD risk.12,52–56 Furthermore, MPO has been
reported to be part of the causal pathway in atherogenesis by
its ability to initiate lipid oxidation and render low-density
lipoprotein modified into a form that fosters macrophage
scavenger receptor recognition, cholesterol accumulation,
and foam cell formation.57 Interestingly, there has been a
paucity of studies on MPO in T1DM. In a small study of 30
children with T1DM, MPO levels were significantly higher than
age-matched controls, as well as associated with atheroscle-
rosis-related structural and functional changes of the arterial
wall.58 The lack of association between MPO and incident
Table 3. Association of Biomarker With Risk of CVD Separately Within Each Treatment Group and Combined, With and Without
Adjustment for HbA1c As a Time-Dependent Covariate*
Biomarker Intervention
Nonadjusted for HbA1c Adjusted for HbA1C
% Change in Risk for a
10% Higher Value (95% CI) P Value
Model
Chi Square
% Change in Risk for
a 10% Higher Value (95% CI) P Value
Model
Chi Square
MPO Intensive 4.2 (2.3, 11.1) 0.21 2.2 4.0 (2.3, 10.8) 0.22 6.5
Conventional 2.2 (2.2, 6.9) 0.33 1.3 2.9 (1.8, 7.8) 0.23 9.72
Total 2.9 (0.8, 6.8) 0.12 3.08 3.3 (0.4, 7.2) 0.083 15.97
PON activity Intensive 4.8 (9.3, 0.1) 0.046 5.9 4.3 (8.9, 0.6) 0.09 8.8
Conventional 4.9 (8, 1.6) 0.0036 10.3 4.6 (8.1, 1) 0.0125 16.9
Total 4.9 (7.4, 2.2) 0.0004 16.1 4.5 (7.3, 1.6) 0.0026 25.5
F2IP Intensive 10.2 (19.8, 0.6) 0.06 4.9 9.4 (19.4, 1.8) 0.097 8.54
Conventional 6.6 (15.6, 3.3) 0.18 2.9 6.1 (15.2, 4.0) 0.23 10.2
Total 8.1 (15, 0.7) 0.034 7.4 7.5 (14.6, 0.2) 0.057 18.4
2,3-dinor-iPF2a-III Intensive 6.1 (11.0, 0.8) 0.02 5.4 6.4 (11.7, 0.8) 0.026 10.5
Conventional 4.6 (10.0, 1.1) 0.11 4.1 4.5 (9.9, 1.2) 0.12 11.6
Total 5.2 (9, 1.4) 0.0086 9.1 5.3 (9.1, 1.4) 0.0092 21.6
2,3-dinor-iPF2a-III indicates 2,3 dinor-8 iso prostaglandin F2a; CI, confidence interval; CVD, cardiovascular disease; F2IP, F2-isoprostane; HbA1c, glycated hemoglobin; MPO,
myeloperoxidase; PON, paraoxonase.
*All analyses used the log (biomarker). To assess the percent change in risk for a higher 10% value in the biomarker, the formula used is: 1009(1.1b1).
DOI: 10.1161/JAHA.117.008368 Journal of the American Heart Association 6
Ox-Stress and CVD Risk in Type 1 Diabetes Mellitus Tang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 30, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
CVD risk in the DCCT/EDIC cohort, even in the unadjusted
model, is therefore unexpected.
Our findings in this study differ compared with previous
studies and challenge the common belief of elevated
oxidative markers as harmful stressors. However, recent
evidence is evolving the interpretation of these markers.
Prospective analysis of urinary F2IP and its metabolites has
also found an inverse association with the risk of developing
type 2 diabetes mellitus, a group known to be highly
susceptible to CVD.59 As previously mentioned, a majority of
evidence linking F2IP to CVD has been cross-sectional. Thus,
the contrasting finding between prospective and cross-
sectional elevation of F2IP suggests dynamic effects over
time that may not be captured through cross-sectional
studies. These observations suggest a need for re-evaluation
of how we interpret systemic oxidative markers. Citing a
recent hypothesis that CVD and diabetes mellitus, in part,
may be mediated by the failure to generate sufficient
reactive oxygen species,60 the inverse relationship between
F2IP and CVD risk in our study can be explained by
measurement of F2IP over time as a marker of systemic
metabolic compensation. These oxidative marker findings
appear to contrast with the observation that increased
antioxidant PON activity is associated with lower CVD risk,
but they may, in fact, represent the balancing act of disease
modulation. However, only additional mechanistic studies
will help expand our understanding. Overall, our findings
present a novel view of biomarker associations in the T1DM
population with a dominant pattern of higher oxidative stress
marker along with increased antioxidant activity associated
with diminished risk of CVD.
Conclusions
In the DCCT/EDIC study, heightened antioxidant activity (as
measured by PON activity), rather than diminished markers of
oxidative stress, is associated with lower CVD risk in T1DM.
None of the biomarkers improved over time with intensifica-
tion of glycemic control.
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1 Case-Cohort Sampling
This study was designed to conduct 3 separate sub-studies of the association of biomarkers with the incidence
of progression of retinopathy, progression of nephropathy, and of cardiovascular disease. For each outcome,
the analysis with 125 cases and 250 controls would provide high power to detect an important association.
The current paper and this supplemental material applies to the analysis of associations with CVD alone.
At the time that the sampling was conducted there were a total of 127 subjects who had experienced a CVD
event (the cases). A random sample of the complete cohort (the sub-cohort) of 350 subjects was selected.
One the subjects did not have any remaining specimens and was not included in the study. Among the
remaining 349 subjects, 29 were CVD cases leaving 320 CVD controls. Thus, the study sample comprised
the 127 CVD cases and the 320 controls, 447 total. To determine the inverse sampling weights, the sampling
fractions were employed within the 4 principal design strata defined by membership in the primary prevention
versus secondary intervention cohort and assignment to the intensive versus conventional therapy.
2 Survey Sampling Analyses
Since a case-cohort design starts with a random sample of the full cohort, augmented by additional cases
in the full cohort, the analysis must be conducted using weights inversely proportional to the sampling
probabilities for cases and controls. These are called Hurwitz-Thompson estimators. Further, the expressions
for the variance (standard error) of the estimators differ from those from simple random sampling. Thus,
the analysis was conducted using sample survey methods that employ the inverse sampling weights. Doing
so, the analysis provides estimates of the analysis results that would be expected had the full cohort been
available for analysis.
3 Missing Data and Multiple Imputation
Unfortunately, there was a modest fraction of missing data. For the biomarker PON, the following table
shows the numbers expected and missing at each point in time and the reason, either due to depletion or
1
 by guest on M
ay 30, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
loss-to-follow-up
DCCT
Baseline
DCCT
Year 1
DCCT
Closeout
EDIC
Year 1/2 Total
Expected 447 446 436 430 1759
Missing n (%) 99 (22.1%) 45 (10.1%) 33 (7.6%) 84 (19.5%) 261 (14.8%)
Depletion n (%) 99 (22.1%) 45 (10.1%) 33 (7.6%) 78 (18.1%) 255 (14.5%)
Loss-to-
follow-up n (%) 0 (0%) 0 (0%) 0 (0%) 6 (1.4%) 6 (0.3%)
The patterns missing for other biomarkers measured in plasma or in urine were similar.
All total, about 15% of the expected data is missing, allowing for CVD outcomes after which missing
measures have no effect on the analysis. Virtually all of these are missing owing to depletion of material in
preceding studies. Of these, the most troubling was the 22% missing the baseline value.
Accordingly the statistical technique of multiple imputation was employed to address the potential impact
of these missing data (Rubin, 1987; van Buuren, 2012). Briefly, an imputation model is developed based on
regression models for each variable as a function of the others, and the model is then applied to each missing
value of each variable to impute a probable value for that instance based on the conditional expectation of
the variable value plus a random error, the latter to preserve the variance and correlation structure of the
data. For these data the imputation was conducted using the MICE procedure (Ragunathan et al. 2001)
implemented in the R-function mice (White et al., 2011). The varables used included age, sex, duration
of diabetes, DCCT primary versus secondary cohort, BMI, smoking, HDL, LDL, MBP, log(AER), and
log(mean updated HbA1c) in all imputations (using the option “include”in function mice), and the CVD,
retinopathy and renal status, as well as the four oxidative stress markers (all four on the log scale) based on
their association with the variable being imputed (using option “minpuc” set to 0.2 in function mice).
Ten complete data sets (with no missing values) were generated and all analyses were then conducted
separately using each data set. The results of the 10 analyses were then averaged using the method of Rubin
and Schenker (1986).
4 Baseline Characteristics (Table 1)
Table 1 of the paper shows the weighted estimates (mean, proportion) of patient characteristics taking into
account the inverse sampling probability weights.
Treatment Group Cohort CVD case/control Weight
Intensive Primary Control 328/55
Secondary Control 331/119
Conventional Primary Control 345/55
Secondary Control 310/91
All All Case 127/127
This allows for the sampling probability of controls for each stratum defined by treatment group and cohort.
Since all known CVD cases were included, the weight for all cases was 1. The sum of the weights in the first
4 strata (all controls), i.e. the sums of the numerators and denominators, equals 1314/340 and adding the
127 cases yields 1441/447.
The STATA svy: mean command provides an estimate of the population mean (µ̂) and an estimate of
the variance of µ̂ [V̂ (µ̂)] accounting for the survey design used to collect the data as captured in the above
weights. Note that for a binary characteristic (e.g. female vs male) the mean is in fact a proportion. In
addition, however, we also desired an estimate of the underlying standard deviation of the observations. Since
the variance of the estimate is σ2/n, where σ2 is the simple variance, then the estimate of the population
standard deviation was simply σ = nV̂ (µ̂) that is reported using the ”estat sd” command.
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5 Longitudinal Biomarker Models (Table 2)
Table 2 presents the longitudinal analysis of each biomarker as the dependent variable. Since patients entered
the study with an HbA1c of about 9% and the intensive group lowered that to 7% during the first year, one
question is whether there was a significant change in the biomarker from year 1 to 2 and whether this change
differed between groups. Then at DCCT closeout subjects were referred to their own healthcare providers
and during during the first 1-2 years the HbA1c dropped from about 9% to 8% in the conventional group
and increased from about 7% to 8% in the intensive group. Thus another question was whether there was a
significant change in the biomarker from year 3 to 4 and whether this change differed between groups
This analysis was conducted using the SAS procedure SURVEYREG in which the patient was a cluster
containing the measures at the 4 time points. The model then contained an effect (class) for group (inten-
sive/conventinal), time (1, 2, 3 or 4) and their interaction. The model used the weights as shown for Table
1.
The estimate function was then used to compute contrasts among the model coefficients to estimate
specific effects such as the change in the biomarker from year 1 to 2 in each group (separately) and the
difference between groups. The estimate statement contrast coefficients were derived using the methods
described in Littell, Freund and Spector (1991).
6 Cox Proportional Hazards Models (Table 3)
Table 3 of the paper then presents prospective Cox Proportional Hazards (PH) models of the association
of each biomarker with the risk of CVD. These models used the biomarker values at times 1 - 4 as a time
dependent covariate. The models used the method of Barlow (1994) as implemented by Therneau and Li
(1999). The models used ”start-stop” notation to indicate the day (since randomization) that the biomarker
value was updated. The models used an offset equal to the log of the weights. The Lin-Wei (1989) robust
estimate of the covariance matrix of the model coefficients was employed to compute confidence limits and
p-values.
The case-cohort design was originally described by Prentice (1986) who provided a generalization of the
original PH model to conduct the analysis. Then Barlow (1994) described a simpler method of analysis that
could be implemented using available software such as the SAS PROC PHREG.
Let ui be an indicator variable to denote membership in the subcohort, = 1 if yes, 0 otherwise; δi.denote
whether the subject had an event at time ti or is right censored at time ti. Then the Barlow (1994) analysis
is based on the likelihood
L˜ (β) =
nCC∏
i=1
 ex′iβ
(1− ui)ex′iβ + 1α
∑
`∈S(ti)
ex
′
`β

δi
, (1)
where nCC is the size of the case-cohort of cases and controls, n is the size of the sub-cohort, and α = n/N
so that the contribution of the subcohort is upweighted by N/n, the inverse sampling weight. In EDIC
the sample weights were computed separately within strata defined by treatment group (intensive versus
conventional) and study cohort (primary prevention versus secondary intervention), 4 strata in total. The
weights were
Treatment Group Cohort Weight
Intensive Primary 348/58
Secondary 363/125
Conventional Primary 378/58
Secondary 352/108
Note that the weights sum to 1441/349. One subject from the original sub-cohort of 350 randomly chosen
subjects did not have any specimens remaining for assay. This subject was not employed in any analyses
herein, so the sub-cohort sample size enters as 349 rather than 350 as originally selected.
The original Barlow model was fit using ”extra” observations in the data set using counting process
structure. This can be generalized to the case where there are separate sampling fractions for cases and
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controls. It is best described by example. Consider different subjects
i ui δi start stop
1 1 0 0 t1
2 1 1 0 t2
3 0 1 t−3 t3
Subject 1 is a sub-cohort control at risk for the entire time to censoring (t1). Subject 2 is a sub-cohort case
that is at risk up too the event time (t2). Subject 3 is an extra case that was not in the subcohort. That
subject is at risk only at the precise event time for that case, where t− = t−  for some small . So all cases
have a record at risk for the instant of the event, and sub-cohort cases also are at risk up to the moment
prior to the event.
With time dependent covariates, subjects 1 and 2 would have records documenting the start and stop
times at which the covariate process changes over time. However, for a non-sub-cohort case, there would be
only one record with (start, stop) times of (t−3 , t3) and where the value of the time-dependent covariate is
the last recorded value.
7 Software
The multiple imputations were performed in R 3.0.0. The analyses for Table 1 were conducted using the SAS
PROC SURVEYMEANS and Stata using the svy: mean command. The analyses in Table were performed
using the SAS PROC SURVEYREG and also using SURVEYMEANS. The analyses in Tables 3 and 4 were
generated using SAS PROC PHREG. SAS version 9.2 or 9.4 was employed, and Stata version 15
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